SESSION 5

ARE WE THERE YET?

CURRENT STATUS OF THE SEARCH FOR A CURE FOR TYPE 1 DIABETES



Christopher Schaaf
PhD Candidate
Barbara Davis Center for
Diabetes




#EPICconf2025







LEONARD THOMPSON





#EPICconf2025



MEANWHILE, IN THE RESEARCH LABS





#EPICconf2025



A BREAKTHROUGH!





#EPICconf2025



TWENTY - EIGHT PAGES. BOTH YEAR. 5 G'CLOCK EDITION TWO CEN's

Coal-Diggers Espect Walkout

Public Appeal for Con-

December Made at University of Toronto Will Be Means of Prolonging Life Coundentily F. G. Beating and C. H. Best Probed Experiments All Last Sammer.

to Be Handred Per BANTING STAKES HIS ALL ON THE RESULT

New Trade Agreement Dealer Looks for a Wat Carada

HOME FOR STUDENTS SHLIT DOWN IN WEST

or on the Sans Philippe Hoy Series With the Linited



People on Both Sides of Lister Border Approbraid an Attack

No Real Massing of Traops Yet. But Many Harryong Reide

Imperials May Separate Itish



#EPICconf2025



DIABETES HAS A TREATMENT

The Nobel Prize in Physiology or Medicine 1923



Photo from the Nobel Foundation archive. Frederick Grant Banting Prize share: 1/2



Photo from the Nobel Foundation archive. John James Rickard Macleod Prize share: 1/2

The Nobel Prize in Physiology or Medicine 1923 was awarded jointly to Frederick Grant Banting and John James Rickard Macleod "for the discovery of insulin"



#EPICconf2025





"Insulin does not belong to me, it belongs to the world" – Frederick Banting




#EPICconf2025



THE CURRENT STANDARD OF CARE

Hybrid closed-loop insulin pump

- CGM communicates blood glucose level to insulin pump
- Insulin pump adjusts basal rates/delivers correction bolus automatically
- User-initiated mealtime bolus
- Minimal input by patient
- Prone to equipment malfunctions
- Requires multiple devices to be worn on body





#EPICconf2025



WHERE DO WE GO FROM HERE?

Prevention

Delaying or stopping onset of the disease



- Effective in Stage 2 diabetes
 - "honeymoon period"
 - Delays onset by an average of 2 years

Functional cure

- Islet transplants
 - Transplant of donor tissue into a patient to replace the lost beta-cells
- Cell therapies
 - Generate new insulin-producing beta cells to transplant into a patient


Goal: to *functionally* cure T1D. Remove any need for exogenous insulin administration (injections/pump infusion) or blood glucose monitoring.



#EPICconf2025



ISLET TRANSPLANTS



The Edmonton Protocol (1999)


- Acquires cadaveric islets from donor
- Islets are isolated from donor pancreas
- Whole Islets are transplanted into recipient hepatic portal vein
- Requires immunosuppressive regimen
- Requires cadaveric donor tissue
 - Massive barrier to its use as a widespread treatment



#EPICconf2025



STEM CELLS AS A SOURCE OF BETA CELLS



Stem cells

- Pluripotency ability to become most cell types in the body
- Provide an "unlimited" source of beta cells
 - Can be expanded indefinitely in the lab


Can be differentiated into insulin-producing beta cells



#EPICconf2025



BETA CELL DIFFERENTIATION PROTOCOLS






#EPICconf2025



STEM CELL THERAPIES TO TREAT DIABETES

Stem cell therapies

- Stem cells maintained in the lab
- Differentiated into beta cells
- Implanted into patient
- Restore insulin production to the patient, without the need for insulin injections/infusions





#EPICconf2025



A BREAKTHROUGH?

The New York Times

A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Stem cell derived beta cell transplant, in combination with immunosuppression

 Still required exogenous insulin administration daily, and maintained diabetic HbA1C levels, albeit reduced. Other studies have shown better results.




#EPICconf2025



THE IMMUNE SYSTEM







#EPICconf2025



IMMUNOSUPPRESSANTS

Immunosupressive regimens

- Lower the immune systems function
- Allows for acceptance of the graft/transplant
 - Medium term (1-3 years)

- Weakened immune system and long-term complications
 - Kidney toxicity
 - High blood pressure
 - Nervous system toxicity
 - Decreased bone marrow
 - Liver toxicity
 - Osteoporosis
 - Flu-like symptoms
 - Nervous system dysregulation






#EPICconf2025



A NEW SOURCE OF STEM CELLS

The Nobel Prize in Physiology or Medicine 2012 was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka "for the discovery that mature cells can be reprogrammed to become pluripotent"

The Nobel Prize in Physiology or Medicine 2012



© The Nobel Foundation. Photo: U. Montan Sir John B. Gurdon Prize share: 1/2



© The Nobel Foundation. Photo: U. Montan Shinya Yamanaka Prize share: 1/2




#EPICconf2025



REPLACEMENT THERAPY FROM THE PATIENT'S OWN CELLS

Induced pluripotent stem cell-derived beta cell transplant is an autologous treatment

- Does not invoke an immune response for host vs graft
- Stem cells provide an "unlimited" source of cells, no donor needed






#EPICconf2025




INDUCED PLURIPOTENT STEM CELL-DERIVED BETA CELLS




Wang, et al. 25 September 2024, Cell


Insulin independence from 75 days post-transplantation



Decrease in glycated hemoglobin



Time-in-target glycemic range > 98%



Patient had received two prior liver transplants, and a whole pancreas transplant.

Pancreas graft was removed one year later due to complications.

Patient was on, and remained on immunosuppression for the duration of the study.



#EPICconf2025



Type 1 diabetes is an autoimmune condition. We need to not only prevent rejection of the transplant, but also the autoimmune response from attacking the newly transplanted tissue



#EPICconf2025




IMMUNOISOLATION DEVICES


Allow for protection of implanted cells from the immune system

- Prevents host graft rejection
 - Allows for allogeneic therapy
- Prevents the autoimmune response from killing the implanted cells

Historically, devices are highly susceptible to fibrotic overgrowth, and a lack of oxygen availability for cells

New clinical trials are underway, with patients already enrolled and dosed







#EPICconf2025




EDITING THE GENOME

Cells are taken from the body, genetically edited in the lab, and returned into the patient.

This is already being done with cancer treatments!

What if we take a similar approach to stem cell derived beta cells? Can we genetically edit cells to evade the immune system?





#EPICconf2025



IMMUNNE-PRIVILEGED STEM CELL DERIVED BETA CELLS



First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

ClinicalTrials.gov ID 1 NCT06239636

Sponsor 1 Per-Ola Carlsson

Information provided by 1 Per-Ola Carlsson, Uppsala University Hospital (Responsible Party)

Last Update Posted 1 2024-12-11

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

January 7, 2025

Cells are alive, functional, and tolerated after 28 days

with no immunosupression



An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

ClinicalTrials.gov ID 1 NCT05565248

Sponsor (i) CRISPR Therapeutics AG

Information provided by CRISPR Therapeutics (CRISPR Therapeutics AG) (Responsible Party)

About VCTX211

VCTX211 is an allogeneic, gene-edited, stem cell-derived investigational therapy for the treatment of T1D, which incorporates additional gene edits that aim to further enhance cell fitness. This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin in response to glucose.



#EPICconf2025



1922


THE TOROND DAILY S AR TORONDO DOCTORS ON TRACK OF DIABETES CURE RAILROAD UNIONS IN U.S. MAY JOIN IN MINERS'STRIKE IN OLD FRANCE IN



2025









#EPICconf2025





"Insulin does not belong to me, it belongs to the world" –Sir Frederick Banting, 1922



#EPICconf2025

